Ā | Group 1 (nā=ā5) | Group 2 (nā=ā10) |
---|---|---|
Median age, years (range) | 37 (34ā45) | 36 (27ā47) |
Sex, n (%) | ||
āMale | 4 (80) | 1 (10) |
āFemale | 1 (20) | 9 (90) |
Baseline OAT, n (%) | ||
āMethadone (ā¤ā30Ā mg)a | 1 (20) | 1 (10) |
āOral buprenorphine lyophilisate | 4 (80) | 0 (0) |
āNone (out of treatment) | - | 9 (90) |
UDS, n (%) | ||
āBuprenorphine | 4 (80) | 2 (20) |
āMethadone | 1 (20) | 4 (40) |
āCocaine | 0 (0) | 9 (90) |
āMorphine | 0 (0) | 10 (100) |
āBenzodiazapine | 0 (0) | 6 (60) |
āAmphetamine | 0 (0) | 2 (20) |
CGI-S score, mean (Ā±āSD) | 2.6 (Ā±ā0.9) | 6.4 (Ā±ā1.0) |
SSQ score, mean (Ā±āSD) | 21.8 (Ā±ā1.9) | 5.6 (Ā±ā4.9) |
CORE-10 score, mean (Ā±āSD) | 5.2 (Ā±ā3.3) | 28.9 (Ā±ā4.2) |